A5418 STUDY OF TECOVIRIMAT FOR HUMAN MONKEYPOX VIRUS (STOMP)
A5418 TECOVIRIMAT 针对人猴痘病毒 (STOMP) 的研究
基本信息
- 批准号:10710436
- 负责人:
- 金额:$ 60.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-26 至 2024-03-25
- 项目状态:已结题
- 来源:
- 关键词:AIDS clinical trial groupAdultAffectAppointmentBloodBreast FeedingChildClinicClinical Trials Data Monitoring CommitteesDataDiseaseDouble-Blind MethodDouble-blind trialEnrollmentEvaluationFundingHomeHumanImmunologic Deficiency SyndromesIndividualInfectionInflammatoryInvestigationLesionLiquid substanceMonitorMonkeypoxMonkeypox virusNational Institute of Allergy and Infectious DiseasePainParticipantPersonsPharmaceutical PreparationsPhase III Clinical TrialsPlacebo ControlPlacebosPoxviridaeProtocols documentationRandomizedResearch PersonnelSafetySamplingSiteSkinSmallpoxSwabSymptomsUnited StatesUnited States Food and Drug AdministrationUnited States National Institutes of HealthVirus Diseasesarmclinical research sitecohortdiarieshealingopen labelparticipant safetypillpregnantvirtual
项目摘要
ACTG A5418: A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease, Study of Tecovirimat for Human Monkeypox Virus (STOMP)
CLINICAL COORDINATION, MONITORING AND EVALUATION OF THE AIDS CLINICAL TRIALS GROUP PROTOCOL A5418 STUDY OF TECOVIRIMAT FOR HUMAN MONKEYPOX VIRUS (STOMP). A5418 (STOMP) is a study of tecovirimat (also known as TPOCC) for the treatment of human monkeypox virus (HMPXV) disease.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring a Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, for the treatment of human monkeypox infection. The NIAID-funded AIDS Clinical Trials Group (ACTG) is leading the study, which is now enrolling adults and children with monkeypox infection in the United States. Study investigators aim to enroll more than 500 people from up to 80 clinical research sites nationwide.
Adults with severe monkeypox, severe immunodeficiency, or severe inflammatory skin conditions; individuals taking certain medications that could affect tecovirimat levels; and pregnant people, people who are breastfeeding and children all will be enrolled in an open-label arm in which all participants receive tecovirimat. Other adult participants—530 total—will be randomly assigned in a 2:1 ratio to receive tecovirimat or placebo pills, which participants will take for 14 days. This part of the trial is double-blind, meaning neither participants nor investigators will know who is receiving placebo or tecovirimat.
Investigators will gather data to determine if participants receiving tecovirimat heal more quickly and have less pain compared with those taking placebo. Participants will be followed for at least 57 days and will be asked to fill out a symptom diary, do daily skin checks at home and attend virtual and in-person clinic appointments. They also will undergo physical exams and will be asked to provide blood and other bodily fluid samples, including swabbing fluid from their lesions.
Data on the safety and efficacy of tecovirimat will be submitted to the FDA. An independent Data and Safety Monitoring Board (DSMB) will monitor participant safety throughout the duration of the study. In addition, any participant in the randomized cohort who progresses to severe disease will be unblinded and given tecovirimat if they were randomized to placebo.
ACTG A5418:一项随机、安慰剂对照、双盲、特考韦瑞治疗人猴痘病毒病的安全性和有效性试验,特考韦瑞治疗人猴痘病毒的研究(STOMP)
艾滋病临床试验组方案A5418 Tecovirimat治疗人猴痘病毒(STOMP)研究的临床协调、监测和评价。 A5418(STOMP)是一项tecovirimat(也称为TPOCC)治疗人猴痘病毒(HMPXV)疾病的研究。
国家过敏和传染病研究所(NIAID),美国国立卫生研究院的一部分,正在赞助一项3期临床试验,评估抗病毒tecovirimat,也称为TPOXX,用于治疗人类猴痘感染。NIAID资助的艾滋病临床试验组(ACTG)正在领导这项研究,该研究目前正在美国招募患有猴痘感染的成人和儿童。研究人员的目标是从全国80个临床研究中心招募500多人。
患有严重猴痘、严重免疫缺陷或严重炎症性皮肤病的成年人;服用某些可能影响tecovirimat水平的药物的个人;孕妇、母乳喂养者和儿童都将参加开放标签组,所有参与者都将接受tecovirimat。其他成年参与者-总共530人-将以2:1的比例随机分配接受tecovirimat或安慰剂药丸,参与者将服用14天。试验的这一部分是双盲的,这意味着参与者和研究人员都不知道谁正在接受安慰剂或tecovirimat。
研究人员将收集数据,以确定与服用安慰剂的参与者相比,接受tecovirimat的参与者是否愈合更快,疼痛更少。参与者将被随访至少57天,并被要求填写症状日记,每天在家进行皮肤检查,并参加虚拟和面对面的诊所预约。他们还将接受体检,并被要求提供血液和其他体液样本,包括病变处的拭子液。
有关tecovirimat的安全性和有效性的数据将提交给FDA。独立的数据和安全性监查委员会(DSMB)将在整个研究期间监测受试者的安全性。此外,如果随机化队列中任何进展为重度疾病的受试者被随机分配至安慰剂组,则将揭盲并给予tecovirimat。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BARBARA DRIVER其他文献
BARBARA DRIVER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BARBARA DRIVER', 18)}}的其他基金
SUPPORT SERVICES FOR THE PREVENTION AND TREATMENT THROUGH A COMPREHENSIVE CARE CONTINUUM FOR HIV-AFFECTED ADOLESCENTS IN RESOURCE CONSTRAINED SETTINGS IMPLEMENTATION SCIENCE NETWORK
通过全面护理连续体为资源有限环境中受艾滋病毒影响的青少年提供预防和治疗支持服务 实施科学网络
- 批准号:
10917617 - 财政年份:2023
- 资助金额:
$ 60.52万 - 项目类别:
SUPPORT SERVICES FOR HIV AIDS CLINICAL TRIAL NETWORKS
HIV 艾滋病临床试验网络的支持服务
- 批准号:
10872942 - 财政年份:2023
- 资助金额:
$ 60.52万 - 项目类别:
CORE NICHD NETWORK CLINICAL SITE SUPPORT FOR IMPAACT RELATED STUDIES
核心 NICHD 网络临床站点支持影响相关研究
- 批准号:
10792687 - 财政年份:2022
- 资助金额:
$ 60.52万 - 项目类别:
STUDY CLOSEOUT FOR THE INTERNATIONAL COHORT STUDY OF CHILDREN BORN TO WOMEN INFECTED WITH ZIKA VIRUS DURING PREGNANCY (ZIP 2.0)
对怀孕期间感染寨卡病毒的妇女所生儿童的国际队列研究即将结束 (ZIP 2.0)
- 批准号:
10701122 - 财政年份:2022
- 资助金额:
$ 60.52万 - 项目类别:
PHASE I STUDY OF PHARMACOKINETICS, SAFETY AND ACCEPTABILITY OF A SINGLE DOSE OF PRETOMANID ADDED TO AN OPTIMIZED BACKGROUND REGIMEN IN CHILDREN WITH RIFAMPICIN RESISTANT TUBERCULOSIS IMPAACT 2034
对患有利福平耐药结核病儿童的单剂量 Pretomanid 的药代动力学、安全性和可接受性的 I 期研究添加到优化背景方案中的影响 2034
- 批准号:
10679271 - 财政年份:2022
- 资助金额:
$ 60.52万 - 项目类别:
SUPPORT SERVICES OF THE HIV AIDS CLINICAL TRIAL NETWORKS
HIV艾滋病临床试验网络的支持服务
- 批准号:
10792689 - 财政年份:2022
- 资助金额:
$ 60.52万 - 项目类别:
IMPAACT RELATED PROTOCOLS FOR THE RESEARCH ON TREATMENT, PREVENTION, DIAGNOSIS AND EPIDEMIOLOGY OF HIV INFECTIONS
HIV 感染的治疗、预防、诊断和流行病学研究的影响相关方案
- 批准号:
10369859 - 财政年份:2021
- 资助金额:
$ 60.52万 - 项目类别:
SECONDARY DATA ANALYSES AND INVESTIGATION OF RESEARCH CONCEPT PROPOSALS FROM THE PROSPECTIVE COHORT OF HIV AND ZIKA IN INFANTS AND PREGNANCY STUDY (HIV-ZIP)
二手数据分析和调查婴儿和妊娠研究中艾滋病毒和寨卡病毒前瞻性队列的研究概念提案 (HIV-ZIP)
- 批准号:
10576710 - 财政年份:2021
- 资助金额:
$ 60.52万 - 项目类别:
ZIP 2.0 STUDY CHILD COHORT WITH INTERIM ANALYSIS OF AGE 30 MONTHS DATA
ZIP 2.0 研究儿童队列,对 30 个月龄数据进行中期分析
- 批准号:
10396161 - 财政年份:2021
- 资助金额:
$ 60.52万 - 项目类别:
HIV AND OTHER IMPAACT RELATED INFECTIOUS DISEASE STUDIES
艾滋病毒和其他影响相关的传染病研究
- 批准号:
9916163 - 财政年份:2019
- 资助金额:
$ 60.52万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 60.52万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 60.52万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 60.52万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 60.52万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 60.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 60.52万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 60.52万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 60.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 60.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 60.52万 - 项目类别:
Grant-in-Aid for Scientific Research (C)